Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis.
The purpose of this study was to compare the clinical outcomes of impacted bone graft with or without recombinant human bone morphogenetic protein-2 (rhBMP-2) for osteonecrosis of the femoral head (ONFH). We examined the effect of bone-grafting through a window at the femoral head-neck junction, kno...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4067369?pdf=render |
| _version_ | 1818948891880456192 |
|---|---|
| author | Wei Sun Zirong Li Fuqiang Gao Zhencai Shi Qidong Zhang Wanshou Guo |
| author_facet | Wei Sun Zirong Li Fuqiang Gao Zhencai Shi Qidong Zhang Wanshou Guo |
| author_sort | Wei Sun |
| collection | DOAJ |
| description | The purpose of this study was to compare the clinical outcomes of impacted bone graft with or without recombinant human bone morphogenetic protein-2 (rhBMP-2) for osteonecrosis of the femoral head (ONFH). We examined the effect of bone-grafting through a window at the femoral head-neck junction, known as the "light bulb" approach, for the treatment of ONFH with a combination of artificial bone (Novobone) mixed with or without rhBMP-2. A total of 42 patients (72 hips) were followed-up from 5 to 7.67 years (average of 6.1 years). The patients with and without BMP were the first group (IBG+rhBMP-2) and the second group (IBG), respectively. The clinical effectiveness was evaluated by Harris hip score (HHS). The radiographic follow-up was evaluated by pre-and postoperative X-ray and CT scan. Excellent, good, and fair functions were obtained in 36, 12, and 7 hips, respectively. The survival rate was 81.8% and 71.8% in the first and second group, respectively. However, the survival rate was 90.3% in ARCO stage IIb, c, and only 34.6% in ARCO stage IIIa (P<0.05). It was concluded that good and excellent mid-term follow-up could be achieved in selected patients with ONFH treated with impacted bone graft operation. The rhBMP-2 might improve the clinical efficacy and quality of bone repair. |
| first_indexed | 2024-12-20T08:54:01Z |
| format | Article |
| id | doaj.art-3a702de03c2147c8a5dc9c17ba3f83bc |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T08:54:01Z |
| publishDate | 2014-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-3a702de03c2147c8a5dc9c17ba3f83bc2022-12-21T19:46:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0196e10042410.1371/journal.pone.0100424Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis.Wei SunZirong LiFuqiang GaoZhencai ShiQidong ZhangWanshou GuoThe purpose of this study was to compare the clinical outcomes of impacted bone graft with or without recombinant human bone morphogenetic protein-2 (rhBMP-2) for osteonecrosis of the femoral head (ONFH). We examined the effect of bone-grafting through a window at the femoral head-neck junction, known as the "light bulb" approach, for the treatment of ONFH with a combination of artificial bone (Novobone) mixed with or without rhBMP-2. A total of 42 patients (72 hips) were followed-up from 5 to 7.67 years (average of 6.1 years). The patients with and without BMP were the first group (IBG+rhBMP-2) and the second group (IBG), respectively. The clinical effectiveness was evaluated by Harris hip score (HHS). The radiographic follow-up was evaluated by pre-and postoperative X-ray and CT scan. Excellent, good, and fair functions were obtained in 36, 12, and 7 hips, respectively. The survival rate was 81.8% and 71.8% in the first and second group, respectively. However, the survival rate was 90.3% in ARCO stage IIb, c, and only 34.6% in ARCO stage IIIa (P<0.05). It was concluded that good and excellent mid-term follow-up could be achieved in selected patients with ONFH treated with impacted bone graft operation. The rhBMP-2 might improve the clinical efficacy and quality of bone repair.http://europepmc.org/articles/PMC4067369?pdf=render |
| spellingShingle | Wei Sun Zirong Li Fuqiang Gao Zhencai Shi Qidong Zhang Wanshou Guo Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis. PLoS ONE |
| title | Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis. |
| title_full | Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis. |
| title_fullStr | Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis. |
| title_full_unstemmed | Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis. |
| title_short | Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis. |
| title_sort | recombinant human bone morphogenetic protein 2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis |
| url | http://europepmc.org/articles/PMC4067369?pdf=render |
| work_keys_str_mv | AT weisun recombinanthumanbonemorphogeneticprotein2indebridementandimpactedbonegraftforthetreatmentoffemoralheadosteonecrosis AT zirongli recombinanthumanbonemorphogeneticprotein2indebridementandimpactedbonegraftforthetreatmentoffemoralheadosteonecrosis AT fuqianggao recombinanthumanbonemorphogeneticprotein2indebridementandimpactedbonegraftforthetreatmentoffemoralheadosteonecrosis AT zhencaishi recombinanthumanbonemorphogeneticprotein2indebridementandimpactedbonegraftforthetreatmentoffemoralheadosteonecrosis AT qidongzhang recombinanthumanbonemorphogeneticprotein2indebridementandimpactedbonegraftforthetreatmentoffemoralheadosteonecrosis AT wanshouguo recombinanthumanbonemorphogeneticprotein2indebridementandimpactedbonegraftforthetreatmentoffemoralheadosteonecrosis |